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Sarcoidosis is a multisystem disease that is characterized 
histologically by the presence of non-caseating epithelioid 
granulomas [1]. Uveitis is the most common ocular mani-
festation, seen in 25–50% of patients [2]. About one quarter 
of patients with ocular involvement will develop severe and 
sight-threatening complications.
The etiology of sarcoidosis is poorly understood. There 
is substantial evidence for a genetic predisposition to sarcoid-
osis overall. Monozygotic twins are more often concordant 
for the disease than dizygotic twins [3,4]. Familial clustering 
occurs in approximately 5–16% of patients [5]. The risk of 
sarcoidosis is increased 2.5-fold for siblings and parents of 
a patient with sarcoidosis [6]. Differences also exist in the 
prevalence and clinical manifestations of the disease in 
different geographic areas and racial groups which could be 
due to genetic differences [7].
Sarcoidosis genetic studies have yielded several poly-
morphisms that have now been consistently associated with 
increased risk of sarcoidosis. The first reported possible 
association between sarcoidosis and a specific gene involved 
class I human leukocyte antigen (HLA-B; Gene ID 3106; 
OMIM 142830) and was published more than 30 years ago 
[8]. Since then, HLA class II antigens (HLA-DRB1 [Gene 
ID 3123; OMIM 142857] and -DQB1 [Gene ID 3119; OMIM 
604305]) have been consistently linked to the susceptibility 
and prognosis of the disease [9,10]. To date, eight genome-
wide association studies (GWASs) have correlated single 
nucleotide polymorphisms (SNPs) with sarcoidosis; these 
studies were performed in European and African American 
populations [6,11-15]. Non-HLA genes that have been associ-
ated in GWASs with sarcoidosis include butyrophilin-like 2 
(BTNL2; Gene ID 56244; OMIM 606000), nucleotide-binding 
oligomerization domain 2 gene (NOD2; Gene ID 64127; 
OMIM 605956), notch homolog protein 4 (NOTCH 4; Gene 
ID 4855; OMIM 164951), ras-related protein RAS23 (RAB23; 
Gene ID 51715; OMIM 606144), and annexin A11 (ANXA11; 
Gene ID 311; OMIM 602572), among others. Polymorphisms 
in genes encoding cytokines (transforming growth factor-
beta, interleukin-8, and tumor necrosis factor-alpha) and 
Toll-like receptor-4 have also been reported to be associated 
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Purpose: Uveitis occurs in a subset of patients with sarcoidosis. The purpose of this study was to determine whether 
genetic variants that have been associated previously with overall sarcoidosis are associated with increased risk of 
developing uveitis.
Methods: Seventy-seven subjects were enrolled, including 45 patients diagnosed with sarcoidosis-related uveitis as 
cases and 32 patients with systemic sarcoidosis without ocular involvement as controls. Thirty-eight single nucleotide 
polymorphisms (SNPs) previously associated with sarcoidosis, sarcoidosis severity, or other organ-specific sarcoidosis 
involvement were identified. Allele frequencies in ocular sarcoidosis cases versus controls were compared using the 
chi-square test, and p values were corrected for multiple hypotheses testing using permutation. All analyses were 
conducted with PLINK.
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with more severe sarcoidosis disease course or particular 
extrapulmonary manifestations [16,17].
In contrast with genetic studies for overall sarcoidosis, 
few genetic studies specifically examined the commonly 
encountered phenotypic variant of ocular involvement 
in sarcoidosis. Thompson et al. found that a complement 
factor H (CFH; Gene ID 3075; OMIM 134370) variant, 
which has been shown to be strongly associated with age-
related macular degeneration, was also associated with 
ocular sarcoidosis when subjects with ocular sarcoidosis 
were compared to sarcoidosis-free controls [18]. Spagnolo 
et al. reported that a polymorphism in heat shock protein-7 
(HSP-70/HOM; Gene ID 3305; OMIM 140559) was associ-
ated with sarcoidosis-related uveitis when patients with 
sarcoidosis-related uveitis were compared to patients with 
sarcoidosis without uveitis and sarcoidosis-free controls [19]. 
Kim et al. investigated the association between 11 IL-23R 
(Gene ID 149233; OMIM 607562) SNPs and susceptibility 
to sarcoidosis in patients with sarcoidosis (58 with and 33 
without uveitis) versus healthy controls [20]. Two of these 
SNPs (rs11465804 and rs11209026) were associated with the 
uveitis subgroup compared to healthy controls. None of these 
findings have been replicated in independent samples.
Sarcoidosis is a phenotypically heterogeneous disease, 
and genetic variation could explain the variability in organ-
specific involvement [21]. We hypothesized that genetic 
variation may predispose certain patients with sarcoidosis to 
uveitis. The purpose of this study was to determine whether 
SNPs that have been associated previously with overall 
sarcoidosis, sarcoidosis severity, or non-pulmonary sarcoid-
osis also increase the risk of developing uveitis in patients 
with sarcoidosis.
METHODS
Participants: This genetic case–control study was approved 
by the Institutional Review Board at the Massachusetts Eye 
and Ear Infirmary (MEEI) and conformed to the tenets of 
the Declaration of Helsinki. This study adhered to the ARVO 
statement on human subjects. Written informed consent was 
obtained from all participants. Participants were enrolled 
from two sources: (1) the MEEI Uveitis Clinics and (2) the 
Partners HealthCare Biobank, a biorepository of consented 
patient DNA samples from patients seen at our affiliated 
general hospitals, the Massachusetts General Hospital and 
Brigham and Women’s Hospital. All patients had documenta-
tion of a complete ophthalmic examination and a thorough 
systemic evaluation before inclusion into the study.
Sarcoidosis definition: All participants included in the 
primary analysis had a diagnosis of sarcoidosis established 
by 1) histological confirmation with evidence of disease 
involvement in either the thorax or two more other organ 
systems or 2) characteristic chest radiographs (bilateral hilar 
lymphadenopathy) without diagnosis of another explana-
tory condition after a minimum of 2 years follow-up. Large 
GWASs and candidate gene studies for sarcoidosis have used 
these definitions [6,14,22,23]. As in these previous studies, 
we included patients who did not have tissue confirmation 
of sarcoidosis because an invasive diagnostic procedure is 
frequently deferred in patients with symmetric hilar lymph-
adenopathy [23].
Control definition: Sarcoidosis without uveitis: For 
the primary analysis, controls were defined as patients 
with sarcoidosis but without uveitis. Absence of uveitis 
was excluded by documentation of normal yearly eye 
examinations.
Case definition: Sarcoidosis with uveitis: For the primary 
analysis, cases were defined as patients with sarcoidosis-
related uveitis. The definition of sarcoidosis-related uveitis 
was based on the criteria set forth by the International Work-
shop on Ocular Sarcoidosis (IWOS). The IWOS defined a 
uveitis that is compatible with sarcoidosis-related uveitis 
based on seven signs: 1) mutton-fat keratic precipitates (KPs)/
small granulomatous KPs and/or iris nodules, 2) trabecular 
meshwork nodules and/or tent-shaped peripheral anterior 
synechiae, 3) vitreous opacities displaying snowballs/strings 
of pearls, 4) multiple chorioretinal peripheral lesions (active 
and/or atrophic), 5) nodular and/or segmental peri-phlebitis 
(± candlewax drippings) and/or retinal macroaneurysm in 
an inflamed eye, 6) optic disc nodule(s)/granuloma(s) and/
or solitary choroidal nodule, and 7) bilaterality [24]. We 
included patients who met the criteria for either definitive 
or presumed sarcoidosis-related uveitis. A diagnosis of 
definitive sarcoidosis-related uveitis was made in the pres-
ence of a compatible uveitis with a confirmatory biopsy of 
any organ. Presumed sarcoidosis-related uveitis was defined 
by a compatible uveitis supported by bilateral hilar lymph-
adenopathy seen on chest imaging without a biopsy. The 
anatomic subtype of uveitis was determined according to the 
Standardization of Uveitis Nomenclature (SUN) criteria [25]. 
Presence versus absence of retinal vasculitis was also noted 
for each patient.
We chose the case and control definitions as detailed 
above because we felt these were the optimal definitions 
for achieving our main purpose which was to identify genes 
that convey risk specifically to uveitis in the setting of 
systemic sarcoidosis. Because some of the previous studies 
that have tried to identify genes for sarcoidosis-associated 
uveitis compared sarcoidosis-associated uveitis patients to 
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sarcoidosis-free controls [18-20], we also recruited sarcoid-
osis-free controls from the Partners HealthCare Biobank 
only for the purpose of trying to replicate this subset of 
original findings with optimal precision. These participants 
were identified as having no history of sarcoidosis and a 
documented normal eye examination on detailed electronic 
medical record review.
Literature review: To identify variants that have been previ-
ously associated with sarcoidosis, sarcoidosis severity, and/
or other organ-specific sarcoidosis, we performed PubMed 
searches with the following criteria without a publication date 
or language limit. One PubMed search was performed using 
the following keywords to identify genome-wide associa-
tion studies for sarcoidosis: (sarcoidosis OR sarcoid) AND 
[(genome wide association) OR GWAS]. Previous candidate 
gene association studies were identified by the following 
PubMed search: [((genetics OR genetic OR gene OR poly-
morphism OR SNP OR allele OR genotype OR variant OR 
variation OR mutation)) AND (sarcoidosis OR sarcoid)]. 
SNPs that were associated with sarcoidosis or complications 
were extracted from the articles identified. A total of 38 SNPs 
were found and are listed in Table 1.
Genotyping: For participants enrolled from the MEEI Uveitis 
clinics, two 10 ml vials of whole blood were drawn on each 
patient at MEEI and frozen at -80 ºC for up to several months. 
Genomic DNA was isolated from whole blood using the 
Gentra Puregene Blood Kit platform at the Broad Institute 
(Cambridge, MA). The 38 SNPs were then genotyped on 
the Sequenom MassARRAY iPLEX 137 platform. HapMap 
control genotyping was performed to ensure genotype 
calling accuracy. For participants enrolled from the Partners 
HealthCare Biobank, whole blood samples were collected as a 
dedicated research draw or as a clinical discard. Whole blood 
was spun to buffy coat with a centrifuge and the buffy coat 
was stored in a freezer for up to several months. The buffy 
coat was then extracted to DNA using either the Autogen’s 
Flexstar (Protocol: Isolation of DNA from 100–500 μl Buffy 
Coat) or Qiagen’s Autopure instruments at the Partners Trans-
lational Genomics Core (Boston, MA). The DNA was then 
stored in an ultralow freezer (-80 ºC). DNA was genotyped on 
the Expanded Multi-Ethnic Genotyping Arrayat the Partners 
Translational Genomics Core (Boston, MA). Imputation was 
performed using the 1000 Genomes reference panel using 
the Michigan Imputation Server and Minimac3. Genotypes 
for the 38 SNPs of interest were extracted from this imputed 
genotype data set and can be found in Appendix 1. Quality 
control for genotyping quality, missingness, Hardy–Weinberg 
equilibrium, and imputation quality were performed on the 
Biobank data using standard protocols. Because the samples 
for this study were genotyped on two different platforms, 
we also performed quality control steps on the two data sets 
(MEEI Uveitis Clinics and Partners HealthCare Biobank) 
jointly.
Statistical analysis: We compared baseline demographic 
and clinical variables between cases and controls with the 
t-test for continuous variables and the chi-square test for 
categorical variables. Any variables that were statistically 
significantly different between the cases and the controls 
were adjusted for in the subsequent analyses. All genetic 
analyses were conducted with the genetic association 
analysis software, PLINK [26]. Multiple hypotheses testing 
correction was done with permutation. A corrected p value 
of less than 0.05 was considered statistically significant. 
The primary analysis compared all sarcoidosis-associated 
uveitis patients (cases) to patients with sarcoidosis without 
uveitis (controls). To eliminate potential bias from differential 
ancestry, a subanalysis including only Caucasian Americans 
was performed. Subanalyses were also performed separately 
in men and women to determine whether there was any 
gender-specific effect. To further elucidate potential asso-
ciations between SNPs and particular anatomic subtypes of 
sarcoidosis-associated uveitis, we performed subanalyses 
examining sarcoidosis-associated anterior uveitis separately 
from the other anatomic subtypes: intermediate uveitis, 
posterior uveitis, and panuveitis. We chose to look at anterior 
uveitis only in the subanalyses as we lacked sufficient power 
to examine the other anatomic subtypes of uveitis, as well as 
retinal vasculitis.
RESULTS
A total of 77 participants were enrolled in this study for the 
primary analysis: 45 patients with sarcoidosis-associated 
uveitis (cases) and 32 patients with systemic sarcoidosis 
without uveitis (controls). The clinical and demographic 
characteristics of all participants are shown in Table 2. Of 
the 45 patients with sarcoidosis-associated uveitis, 24 patients 
had anterior uveitis, seven had intermediate uveitis, four 
had posterior uveitis, and ten had panuveitis. In addition, 
two patients with posterior uveitis and two patients with 
panuveitis had evidence of retinal vasculitis. Twenty-eight 
of the 45 sarcoidosis-related uveitis cases had biopsy-proven 
sarcoidosis, and 17 participants had presumed sarcoidosis 
based on the presence of bilateral hilar adenopathy. Of the 32 
controls without uveitis, 27 had biopsy-proven sarcoidosis, 
and five had sarcoidosis diagnosed based on bilateral hilar 
adenopathy. There were no statistically significant differ-
ences in the age, gender, race, or disease duration between the 
Molecular Vision 2018; 24:59-74 <http://www.molvis.org/molvis/v24/59> © 2018 Molecular Vision 
62
Ta
b
l
e
 1
. 3
8 
SN
PS
 P
r
e
v
io
u
Sl
y
 a
SS
o
c
ia
T
e
d
 w
iT
h
 Sa
r
c
o
id
o
Si
S, 
Sa
r
c
o
id
o
Si
S S
e
v
e
r
iT
y
 o
r
 o
r
g
a
N
-S
Pe
c
if
ic
 Sa
r
c
o
id
o
Si
S i
N
v
o
lv
e
m
e
N
T.
G
en
e 
N
am
e 
or
 L
oc
us
SN
P
R
ef
er
en
ce
A
ss
oc
ia
tio
n 
w
ith
AN
XA
11
rs
27
89
67
9*
H
of
m
an
n 
et
 a
l. 
20
08
 [1
2]
Sa
rc
oi
do
si
s
AN
XA
11
rs
25
73
34
6*
H
of
m
an
n 
et
 a
l. 
20
08
 [1
2]
Sa
rc
oi
do
si
s
AN
XA
11
rs
10
49
55
0*
H
of
m
an
n 
et
 a
l. 
20
08
 [1
2]
Sa
rc
oi
do
si
s
AN
XA
11
rs
61
86
00
52
Le
vi
n 
et
 a
l. 
20
12
 [2
2]
Sa
rc
oi
do
si
s i
n 
A
fr
ic
an
 A
m
er
ic
an
s
A
N
X
A
11
 a
nd
 P
L
A
C
9
rs
19
53
60
0*
H
of
m
an
n 
et
 a
l. 
20
08
 [1
2]
Sa
rc
oi
do
si
s
BT
N
L2
rs
92
68
48
0*
A
dr
ia
nt
o 
et
 a
l. 
20
12
 [6
]
Sa
rc
oi
do
si
s
B
T
N
L2
 (
up
st
re
am
)
rs
92
68
48
2*
A
dr
ia
nt
o 
et
 a
l. 
20
12
 [6
]
Sa
rc
oi
do
si
s
C
D
C
C
88
B
rs
67
19
76
*
Fi
sc
he
r e
t a
l. 
20
12
 [1
4]
Sa
rc
oi
do
si
s
C
D
C
C
88
B
rs
47
97
77
*
Fi
sc
he
r e
t a
l. 
20
12
 [1
4]
Sa
rc
oi
do
si
s
C
C
R 
5
rs
17
99
98
7
M
cD
ou
ga
l e
t a
l. 
20
09
 [3
6]
Er
yt
he
m
a 
no
do
su
m
 in
 sa
rc
oi
do
si
s
C
C
R 
5
rs
33
3
Fi
sc
he
r e
t a
l. 
20
08
 [3
7]
Lo
fg
re
n 
sy
nd
ro
m
e
Lo
cu
s 1
q2
4.
3
rs
12
03
50
82
Fi
sc
he
r e
t a
l. 
20
11
[3
8]
A
cu
te
 sa
rc
oi
do
si
s
C
F
H
 Y
40
2H
rs
10
61
17
0
Th
om
ps
on
 e
t a
l. 
20
13
 [1
8]
O
cu
la
r s
ar
co
id
os
is
C
10
O
R
F
67
/1
0p
12
.2
rs
13
98
02
4*
Fr
an
ke
 e
t a
l. 
20
08
 [3
9]
Sa
rc
oi
do
si
s
H
ER
C2
rs
91
69
77
Fi
sc
he
r e
t a
l. 
20
11
 [3
8]
Sa
rc
oi
do
si
s
IL
23
R
rs
11
46
58
04
 (i
nt
ro
n 
8)
K
im
 e
t a
l. 
20
11
 [2
0]
Sa
rc
oi
do
si
s, 
Sa
rc
oi
do
si
s-
as
so
ci
at
ed
 u
ve
iti
s
IL
23
R
rs
75
11
78
47
 (i
nt
ro
n 
6)
K
im
 e
t a
l. 
20
11
 [2
0]
Sa
rc
oi
do
si
s
H
SP
-7
0/
H
om
rs
20
75
80
0
Sp
ag
no
lo
 e
t a
l. 
20
07
 [1
9]
Sa
rc
oi
do
si
s-
as
so
ci
at
ed
 u
ve
iti
s
H
SP
-7
0/
H
om
rs
10
43
62
0
Sp
ag
no
lo
 e
t a
l. 
20
07
 [1
9]
Sa
rc
oi
do
si
s
IL
23
R
rs
11
20
90
26
Fi
sc
he
r e
t a
l. 
20
11
 [2
0,
 3
8]
C
hr
on
ic
 sa
rc
oi
do
si
s
IL
2R
A
rs
12
72
24
89
†
Zh
ou
 e
t a
l. 
20
12
 [4
0]
C
om
pl
ic
at
ed
 sa
rc
oi
do
si
s
LT
A
rs
90
92
53
M
cD
ou
ga
l e
t a
l. 
20
09
 [3
6]
Er
yt
he
m
a 
no
do
su
m
 in
 sa
rc
oi
do
si
s
NO
TC
H
4
rs
71
52
99
*
A
dr
ia
nt
o 
et
 a
l. 
20
12
 [6
]
Sa
rc
oi
do
si
s
O
S9
rs
11
17
23
00
*
H
of
m
an
n 
et
 a
l. 
20
13
 [1
3]
Sa
rc
oi
do
si
s
O
S9
rs
70
10
07
*†
H
of
m
an
n 
et
 a
l. 
20
13
 [1
3]
Sa
rc
oi
do
si
s
O
S9
rs
79
92
65
*†
H
of
m
an
n 
et
 a
l. 
20
13
 [1
3]
Sa
rc
oi
do
si
s
RA
B2
3
rs
10
40
46
1*
H
of
m
an
n 
et
 a
l. 
20
11
 [2
6]
Sa
rc
oi
do
si
s
T
G
F
-β
2
rs
18
91
46
7
K
ru
it 
et
 a
l. 
20
06
 [4
1]
Pu
lm
on
ar
y 
fi
br
os
is
 in
 sa
rc
oi
do
si
s
T
G
F
-β
3
rs
39
17
20
0
K
ru
it 
et
 a
l. 
20
06
 [4
1]
Pu
lm
on
ar
y 
fi
br
os
is
 in
 sa
rc
oi
do
si
s
T
G
F
-β
3
rs
39
17
16
5
K
ru
it 
et
 a
l. 
20
06
 [4
1]
Pu
lm
on
ar
y 
fi
br
os
is
 in
 sa
rc
oi
do
si
s
TL
R4
rs
49
86
79
0
Pa
bs
t e
t a
l. 
20
06
 [1
6]
C
hr
on
ic
 sa
rc
oi
do
si
s
T
N
F
-α
rs
18
00
62
9
M
cD
ou
ga
l e
t a
l. 
20
09
 [3
6]
Er
yt
he
m
a 
no
do
su
m
 in
 sa
rc
oi
do
si
s
H
LA
- D
Q
A1
rs
17
84
36
04
*
A
dr
ia
nt
o 
et
 a
l. 
20
12
 [6
]
Sa
rc
oi
do
si
s
Molecular Vision 2018; 24:59-74 <http://www.molvis.org/molvis/v24/59> © 2018 Molecular Vision 
63
G
en
e 
N
am
e 
or
 L
oc
us
SN
P
R
ef
er
en
ce
A
ss
oc
ia
tio
n 
w
ith
H
LA
- D
Q
B1
rs
14
92
88
32
9*
A
dr
ia
nt
o 
et
 a
l. 
20
12
 [6
]
Sa
rc
oi
do
si
s
H
LA
- D
RA
rs
71
92
*
A
dr
ia
nt
o 
et
 a
l. 
20
12
 [6
]
Sa
rc
oi
do
si
s
H
LA
- D
RA
rs
71
94
*
A
dr
ia
nt
o 
et
 a
l. 
20
12
 [6
]
Sa
rc
oi
do
si
s
H
LA
- D
RB
1
rs
61
56
72
*
A
dr
ia
nt
o 
et
 a
l. 
20
12
 [6
]
Sa
rc
oi
do
si
s
H
LA
- D
RB
5
rs
17
20
36
12
*
A
dr
ia
nt
o 
et
 a
l. 
20
12
 [6
]
Sa
rc
oi
do
si
s
*S
N
P
s 
th
at
 w
er
e 
ge
no
m
e-
w
id
e 
si
gn
ifi
ca
nt
 fi
nd
in
gs
 in
 th
e 
pr
ev
io
us
 s
tu
di
es
. †
 P
ro
xy
 S
N
P
s 
fo
r 
or
ig
in
al
ly
 r
ep
or
te
d 
S
N
P 
rs
10
50
04
5
Molecular Vision 2018; 24:59-74 <http://www.molvis.org/molvis/v24/59> © 2018 Molecular Vision 
64
sarcoidosis-related uveitis cases and the controls (all p>0.05). 
All patients had some degree of pulmonary involvement.
Table 3 shows the association results for the primary 
analysis that compared cases with sarcoidosis-associated 
uveitis to controls with sarcoidosis but no uveitis. Three SNPs 
(rs333, rs149288329, and rs12035082) failed the genotyping 
quality control parameters and were excluded from the study; 
thus, the results for 35 SNPs are presented in Appendix 1 
and Table 3. SNPs rs1040461 in RAB23 and rs61860052 in 
ANXA11 on chromosomes 6 and 10, respectively, were associ-
ated with sarcoidosis-associated uveitis after p value correc-
tion for multiple hypotheses testing (Pcorr). The T allele of 
rs1040461 and the A allele of rs61860052 were found to occur 
more frequently in patients with sarcoidosis-related uveitis 
(Pcorr=0.01 and Pcorr=0.02, respectively).
In this study, 71.4% (55/77) of the patients were Cauca-
sian Americans. We performed a subanalysis in Caucasian 
Americans only to address potential bias from differential 
ancestry. The A allele of rs61860052 continued to be asso-
ciated with uveitis in this subgroup (odds ratio [OR]=4.96, 
Pcorr=0.01). The T allele rs1040461 was no longer associated 
to a statistically significant degree, although the direction of 
effect was consistent with the finding in the overall group. In 
addition, two other variants were statistically significantly 
associated with uveitis in Caucasian Americans: the T allele 
of rs17203612 (Pcorr=0.009) and the C allele of rs615672 
(Pcorr=0.04).
In the subanalysis of women only, the T allele of 
rs1040461 (Pcorr=0.04) and the T allele of rs17203612 
(Pcorr=0.03) were associated with uveitis in sarcoidosis in 
women after correction for multiple hypothesis testing. No 
statistically significant associations were identified in the 
men-only subanalysis.
Table 4 shows the association results for the subanalyses 
for anterior uveitis. Both of the statistically significantly 
associated variants in the main analysis (rs1040461 and 
rs618600520) were also statistically significant in the 
subanalysis that compared sarcoidosis-associated anterior 
uveitis versus patients with sarcoidosis without uveitis. The 
HLA-DRB5 (Gene ID 3127; OMIM 604776) variant that was 
significant in the Caucasian American– and female-only 
analyses (rs17203612), was also statistically significant in 
the anterior uveitis subanalysis; this variant was not statisti-
cally significant in the main analysis. Three other variants 
were also statistically significantly associated in the anterior 
uveitis subanalyses but not statistically significant in the 
main analysis: the T allele of rs7192 (Pcorr=0.007), the G 
allele of rs7194 (Pcorr=0.006), and the A allele of rs1800629 
(Pcorr=0.03). When patients with sarcoidosis-associated ante-
rior uveitis were compared to patients with other anatomic 
subtypes (intermediate, posterior, and panuveitis combined), 
these three variants remained statistically significantly 
associated with anterior uveitis. Additionally, the T allele 
of rs3917165 was statistically significantly associated in the 
analysis of sarcoidosis-associated anterior uveitis versus other 
anatomic subtypes of uveitis but not in the analysis of anterior 
uveitis-only compared to patients with sarcoidosis without 
uveitis.
For the three previous studies which identified genetic 
associations with sarcoidosis-associated uveitis specifically 
[18-20], we extracted data on those SNPs on 102 sarcoidosis-
free healthy controls. We compared the sarcoidosis-associated 
uveitis cases to these healthy controls to mimic the design in 
Table 2. cliNical aNd demograPhic characTeriSTicS of caSeS aNd coNTrolS.
Patient characteristics Cases: Sarcoidosis-related uveitis (n = 45)*
Controls: Sarcoidoisis without 
uveitis (n = 32)†
P value
Age mean (SD), years  58.9 (13.5) 56.7 (11.1) 0.44
Gender Male 14 15 0.16
Female 31 17
Mean duration of sarcoidosis 
(SD), years
 8.8 (7.4) 10.0 (10.5) 0.55
Race CA 31 25 0.23
AA 10 3
HA 3 2
AA 1 2
SD=standard deviation, CA=Caucasian American, AA=African American, HA=Hispanic American, AA=Asian American *Includes 36 
cases recruited from the MEEI Uveitis Clinics and 9 cases recruited from the Partners HealthCare Biobank. † Includes 10 controls re-
cruited from the MEEI Uveitis Clinics and 22 controls recruited from the Partners HealthCare Biobank.
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the previous studies. We were not able to replicate any of the 
findings to a statistically significant degree.
DISCUSSION
In this study, four variants that had been previously asso-
ciated with overall sarcoidosis were found to be associated 
with sarcoidosis-associated uveitis in the entire cohort or 
in a subpopulation. The most consistent evidence for asso-
ciation was with SNP rs1040461. It was associated with 
sarcoidosis-associated uveitis in the overall population, as 
well as in the women-only and sarcoidosis-associated ante-
rior uveitis versus non-ocular sarcoidosis subanalysis, and 
the effect was in the same direction as that seen originally 
for overall sarcoidosis. This SNP was initially identified as 
a novel susceptibility locus for sarcoidosis in 2011 as part of 
a genome-wide association study; however, the researchers 
did not evaluate ocular involvement in that study [27]. In that 
study, the T allele increased the risk of developing sarcoidosis 
(OR = 1.68, Pcorr = 0.01). This association was replicated in 
an independent case–control sample, and quantitative mRNA 
expression studies pointed to the RAB23 gene as the most 
likely to be implicated in pathogenesis by this variant [27]. In 
the current study, this association is the same direction with 
the T allele increasing the risk of developing sarcoidosis-asso-
ciated uveitis. RAB23 is proposed to be involved in antibacte-
rial defense and regulation of the sonic hedgehog signaling 
pathway [28]. Many reports describe the presence of micro-
bial cell wall agents in tissues of patients with sarcoidosis, 
and several clinical studies have demonstrated the occurrence 
of microbes in patients with sarcoidosis [29,30].
This association of rs1040461 did not reach statis-
tical significance in the Caucasian American subanalysis 
(Pcorr=0.10). This may have been due to reduced power in 
this subanalysis. Although the association in this subanalysis 
did not reach statistical significance, the direction of effect 
was consistent with the direction in the overall group with the 
T allele being more frequent in cases. The T allele frequency 
was 5% in the Caucasian American cases versus 0% of the 
Caucasian American controls. The direction of effect was 
also consistent in African Americans where the T allele 
frequency was 10% in the African American cases versus 
0% in the African American controls.
The other allele that was statistically significantly asso-
ciated with sarcoidosis-associated uveitis in the primary 
analysis was the A allele of rs61860052. The SNP rs61860052 
in ANXA11, which encodes the annexin A11 protein, was 
associated with sarcoidosis initially in an African American 
population (p=0.01) in 2013 [22]. In that study the frequencies 
of the A allele were 1% and 2% in their cases and controls, 
respectively. In the current study, the frequency of the A 
allele was 13.5% in the sarcoidosis uveitis cases versus 3% 
in the controls overall. Thus, the A allele, which was asso-
ciated with lower risk of overall sarcoidosis in the initial 
African American study, was associated with a higher risk 
of sarcoidosis-associated uveitis in the current study. When 
we examined the allele frequencies in Caucasian Ameri-
cans and African Americans separately in this study, the A 
allele was increased in sarcoidosis-associated uveitis in both 
populations: The A allele frequency was 5% in the African 
American cases versus 0% in the African American controls 
and 17.7% in the Caucasian American cases versus 4% in the 
Caucasian American controls. For comparison, the popula-
tion frequencies of this allele in the 1000 Genomes database 
are 10% in Europeans and 0.3% in Africans, respectively. 
The association of this allele also achieved significance in 
the Caucasian American–only analysis and the sarcoidosis-
associated anterior uveitis versus non-ocular sarcoidosis 
subanalysis.
The reason why the allele in this gene, which decreases 
risk of overall sarcoidosis, would increase the risk of 
sarcoidosis-associated uveitis is unclear. It is possible this 
variant confers a specific risk to the phenotype of sarcoidosis-
associated uveitis. An alternative explanation for this finding 
is that because of the relatively low allele frequency, particu-
larly with African ancestry, there is instability in the present 
results, and they represent an artifact rather than a true asso-
ciation. Annexins have been previously implicated in autoim-
mune disorders, and annexin A11 is among the few proteins 
that are detectable in human B-cell exosomes [6,22,31,32]. 
Exosomes are thought to induce immune responses or toler-
ance depending on their cellular origin. Their role in the 
activation of B-cells in sarcoidosis has been proposed, and 
this activation could lower the threshold for T-cell activation 
[33,34]. Decreased activation of CD8+ and CD19+ immune 
cells is a proposed mechanism for sarcoidosis [12].
Two additional variants were associated with uveitis only 
in the Caucasian Americans subanalysis: rs17203612 and 
rs615672. These variants were originally identified as novel 
susceptibility loci for sarcoidosis in genome-wide associa-
tion studies [6,12]. Both are within major histocompatibility 
complex (MHC) genes on chromosome 6, in HLA-DRB5 and 
HLA-DRB1, respectively. The MHC class II region is known 
for its major role in immune-mediated disorders [35]. Asso-
ciation of HLA-DRB1 with uveitis has also been identified in 
juvenile idiopathic arthritis, and the HLA-DRB1*1301 allele 
is associated with ANA positivity [36]. In addition to being 
significant in the Caucasian Americans subanalysis, the T 
allele at rs17203612 was associated with sarcoidosis-associated 
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uveitis in the women-only and anterior uveitis–only versus 
patients with sarcoidosis without uveitis subanalyses. In the 
original study, the T allele of rs17203612 increased the risk 
of sarcoidosis in African Americans (OR=1.56, Pcorr=2.66 
× 10−5) and in Caucasian Americans (OR=1.58, Pcorr=1.82 
× 10−8) [6]. In the current study, the T allele frequency of 
rs17203613 was 53% in the Caucasian American cases with 
sarcoidosis-associated uveitis versus 28% in the Caucasian 
American controls with sarcoidosis but without uveitis. In 
the women-only analysis, the allele frequency was 41% in 
cases versus 17.5% in controls. The direction of effect was 
also consistent in the men-only analysis (allele frequencies 
of 40% in cases versus 33% in controls) although it did not 
reach statistical significance perhaps because of the limited 
sample size. Therefore, the same allele that increased risk of 
sarcoidosis overall in the original study also increases risk 
of sarcoidosis-associated uveitis in the current study. The 
direction of effect was also the same for the primary analysis 
that included all ancestry groups but was shy of achieving 
statistical significance.
The G allele of rs615672 was associated with an increased 
risk of uveitis in the Caucasian American–only analysis. The 
original association between the G allele of rs615672 and 
sarcoidosis was found in African Americans (OR=0.68, p=7.9 
× 10−4) and in Caucasian Americans (OR=0.81, p=0.008) 
[6]. In the present study, the G allele frequency of rs615672 
was 71% in cases versus 52% in controls among Caucasian 
Americans and 25% in cases versus 16.7% in controls among 
African Americans. Therefore, similar to the results for 
rs61860052, the allele that decreased risk for sarcoidosis in 
the original study increased risk of sarcoidosis-associated 
uveitis in the current study. We cannot rule out that this might 
be a false positive finding because of the small sample in 
this study. The population frequencies of this allele in the 
1000 Genomes database are 78% in Europeans and 51% in 
Africans.
The subanalyses examining whether particular geno-
types could be correlated to the specific anterior subtype 
of sarcoidosis-associated uveitis revealed that the two SNPs 
identified in the primary analysis (rs1040461 and rs61860052) 
were statistically significant in the analysis where only 
patients with sarcoidosis-associated anterior uveitis were 
cases. Three variants were statistically significantly associ-
ated with anterior uveitis but were not statistically signifi-
cantly associated with uveitis in the primary analysis: rs7192, 
rs7194, and rs1800629. These variants were statistically 
significant when anterior uveitis cases were compared to 
patients with sarcoidosis without uveitis and when anterior 
uveitis cases were compared to patients with intermediate 
uveitis, posterior uveitis, and panuveitis. Additionally, the 
T allele of rs3917165 was statistically significantly associ-
ated in the analysis of sarcoidosis-associated anterior uveitis 
versus other anatomic subtypes of uveitis but not in the main 
analysis or the analysis of anterior uveitis–only compared 
with patients with sarcoidosis without uveitis. These results 
indicate that these variants could specifically modify risk for 
anterior uveitis, but further investigation in larger data sets 
is necessary.
Variants rs7192 and rs7194 are located in the HLA-DRA 
(Gene ID 3122; OMIM 142860) gene which encodes the alpha 
subunit of the HLA-DR loci and assists with the presentation 
of peptides derived from extracellular proteins. In a previous 
study, HLA-DRA was shown to be associated with uveitis, 
though this study did not test specifically for anterior uveitis 
[37]. Variant rs1800629 is located in the promoter of the 
TNF-α gene (Gene ID 7124; OMIM 191160). The A allele 
of this SNP, which had an allele frequency of 5% of patients 
with sarcoidosis-associated anterior uveitis, 17% of patients 
with sarcoidosis without uveitis, and 29% of patients with 
other anatomic subtypes of sarcoidosis-associated uveitis 
other than anterior uveitis, is associated with increased 
expression of TNF-α. One interpretation of these data is that 
increased TNF-α expression may specifically associated 
with increased risk of intermediate uveitis, posterior uveitis, 
and panuveitis, which are typically more severe and visually 
threatening than anterior uveitis. This SNP, particularly the A 
allele, is associated with several autoimmune diseases, such 
as ankylosing spondylitis, rheumatoid arthritis, and systemic 
lupus erythematosus [38]. Variant rs3917165 is located in the 
TGFB3 gene (Gene ID 7043; OMIM 190230) which encodes 
the transforming growth factor beta-3 protein: a cytokine 
involved in cell differentiation, embryogenesis, and possibly 
wound healing. TGFB3 has been previously described to be 
associated with uveitis, but specific subtypes have not been 
examined [39].
The present results differ from those found in previous 
genetic studies of sarcoidosis-associated uveitis. One impor-
tant difference between the present study and most of these 
previous studies is that the controls in the present study 
were patients with sarcoidosis and no uveitis, as opposed to 
healthy controls without sarcoidosis. The primary analysis 
case–control definition was designed specifically to identify 
genes that convey risk to uveitis, whereas the previous study’s 
case–control definition could also have been detecting risk 
alleles for sarcoidosis overall. For example, Thompson et al. 
performed a study comparing 41 subjects with ocular sarcoid-
osis to 393 sarcoidosis-free controls [18]. They found that the 
C allele at rs1061170 in CFH was present at a higher frequency 
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in the cases versus controls (48.7% versus 35%, OR=1.72, 
p=0.018). When we used the same case–control definition, 
we also found that the C allele was more frequent in cases 
than controls, although it did not reach statistical significance 
(OR=1.34, p=0.28). However, in the primary analysis case–
control definition, the C allele was slightly more common 
in the controls (34.4% in cases, 37.5% in controls, OR=0.88, 
p=0.77). Therefore, it is possible that this variant is associated 
with sarcoidosis overall, rather than sarcoidosis-associated 
uveitis specifically.
Similarly, Kim et al. performed a study comparing 91 
subjects with sarcoidosis including 58 with ocular sarcoidosis 
to 104 sarcoidosis-free controls [20]. They showed among 11 
IL-23R SNPs, two of the SNPs, rs11465804 and rs11209026, 
were associated with the uveitis subgroup compared to 
healthy controls without sarcoidosis. We did not find any 
association with these two SNPs in the primary analysis, and 
the direction of effect observed was not consistent with the 
original study. When we attempted to replicate the findings 
from this study more precisely using a control definition that 
matched theirs of sarcoidosis-free healthy controls, we still 
were not able to replicate the results despite having similar 
power: The G allele of rs11465804 was present in 6.7% of 
cases and 8.9% of healthy controls (OR=0.73 and p=0.52), and 
the A allele of rs11209026 was present in 7.0% of cases and 
7.4% of healthy controls (OR=0.94 and p=0.89).
The third previous study that looked for genetic asso-
ciations for sarcoidosis-associated uveitis specifically was 
conducted by Spagnolo et al. They evaluated five SNPs in 
270 Caucasian American patients with sarcoidosis, including 
88 with sarcoid-related uveitis, and in 347 matched healthy 
control subjects [19]. They reported that the HSP-70/Hom 
rs2075800 G allele was associated with sarcoidosis-related 
uveitis. The HSP-70/Hom  rs2075800 G allele frequency was 
higher in the sarcoid-uveitis group than in the sarcoid non-
uveitis and healthy control groups. We did not find a statis-
tically significant difference for this allele in the primary 
analysis, although the direction of effect was the same as 
that seen in the Spagnolo et al. study. One reason that this 
association may not have reached statistical significance is 
the more limited power in the current study.
Few genetic studies specifically examined the commonly 
encountered phenotypic variant of ocular involvement in 
sarcoidosis. The strengths of the present study include well-
characterized case and control definitions to specifically 
detect an association with the uveitis complication among 
patients with sarcoidosis. We also examined the largest 
number of variants for this phenotype to date. All 38 SNPs 
chosen had a strong a priori hypothesis for being associated 
with sarcoidosis-associated uveitis. Previously, the largest 
number of SNPs examined for this phenotype was five [19].
However, the present study has several limitations. First, 
we had a limited sample size, and larger samples are needed 
to confirm these initial findings. We performed simula-
tions to characterize the power of this study for a range of 
allele frequencies and effect sizes using the Genetic Power 
Calculator. Although we had greater than 80% power to 
detect genetic variants of large effect sizes, as that seen with 
rs61860052, we had limited power to detect associations 
with variants of modest effect. For example, we had only 
30% power to detect a variant with a risk allele frequency 
of 30% and an OR of 1.5. Therefore, it is possible that some 
of the other variants examined in this study might be associ-
ated with ocular sarcoidosis, but larger sample sizes would 
be required to detect the association. Additionally, we were 
unable to examine certain subtypes of sarcoidosis-associated 
uveitis (retinal vasculitis and intermediate uveitis, posterior 
uveitis, and panuveitis) because of the limited sample size. 
We included participants of different ethnicities to maximize 
the power of the analyses, but this diversity has the potential 
to introduce population stratification and lead to false posi-
tive findings. We mitigated this problem by performing a 
subanalysis of Caucasian American participants only and by 
examining allele frequencies in Caucasian Americans and 
African Americans separately and did not find any overt 
evidence of population stratification. We genotyped partici-
pants on two different platforms which can also lead to false 
positive findings. To mitigate this problem, we performed 
strict quality control of genotyping in both data sets and 
examined the genotyping results carefully across the two 
platforms, particularly for the significant findings.
There were also limitations regarding clinical character-
ization of the patients. Approximately half of the participants 
had presumed sarcoidosis based on bilateral hilar adenopathy 
but did not have biopsy-proven disease. However, most large 
GWASs and candidate gene studies have included patients 
with sarcoidosis who did not have biopsy-proven sarcoid-
osis as long as they have bilateral hilar adenopathy and 
other supportive clinical findings according to established 
criteria [6,14,22,23]. Although the duration of sarcoidosis 
was slightly longer in the controls than in the cases, there 
is still the potential for misclassification bias; for example, 
some of the controls may develop eye involvement with 
longer follow-up. Misclassification, however, should bias the 
results to the null so this is unlikely to change the findings 
that were statistically significant. It is also possible that the 
associations we detected are associations with more severe 
sarcoidosis rather than uveitis specifically. However, we did 
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not find any statistically significant differences between the 
cases and controls for other SNPs previously associated with 
sarcoidosis severity specifically.
In conclusion, we identified polymorphisms that were 
previously associated with increased risk of overall sarcoid-
osis to also be associated with an increased risk of uveitis 
in sarcoidosis. The findings of this study will need to be 
replicated in larger, independent patient populations. If the 
findings are confirmed, fine-mapping of these genetic loci 
may yield insights into the underlying pathogenesis of ocular 
involvement in sarcoidosis and help identify potential treat-
ment targets.
APPENDIX 1. GENOTYPE DATA FOR SNPS 
ASSOCIATED WITH SARCOIDOSIS IN PATIENTS 
WITH SARCOIDOSIS-ASSOCIATED UVEITIS 
(CASES) VS. SARCOIDOSIS PATIENTS WITHOUT 
UVEITIS (CONTROLS).
To access the data, click or select the words “Appendix 1”
ACKNOWLEDGMENTS
Funding for this study was provided by a research grant from 
the Massachusetts Lions Eye Research Fund. We wish to 
thank Partners HealthCare Biobank for providing samples, 
genomic data, and health information data for a part of our 
study.
REFERENCES
1. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier 
JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, 
Rose C, Selroos O, Semenzato G, Sharma OP. ATS/ERS/
WASOG statement on sarcoidosis. American Thoracic 
Society/European Respiratory Society/World Association of 
Sarcoidosis and other Granulomatous Disorders.  Sarcoidosis 
Vasc Diffuse Lung Dis  1999; 16:149-73. [PMID: 10560120].
2. Bodaghi B, Touitou V, Fardeau C, Chapelon C, LeHoang P. 
Ocular sarcoidosis.  Presse Med  2012; 41:e349-54. [PMID: 
22595776].
3. Familial associations in sarcoidosis. A report to the Research 
Committee of the British Thoracic and Tuberculosis Associa-
tion.  Tubercle  1973; 54:87-98. [PMID: 4766014].
4. Sverrild A, Backer V, Kyvik KO, Kaprio J, Milman N, 
Svendsen CB, Thomsen SF. Heredity in sarcoidosis: a 
registry-based twin study.  Thorax  2008; 63:894-6. [PMID: 
18535119].
5. Rybicki BA, Kirkey KL, Major M, Maliarik MJ, Popovich J Jr, 
Chase GA, Iannuzzi MC. Familial risk ratio of sarcoidosis in 
African-American sibs and parents.  Am J Epidemiol  2001; 
153:188-93. [PMID: 11159165].
6. Adrianto I, Lin CP, Hale JJ, Levin AM, Datta I, Parker R, 
Adler A, Kelly JA, Kaufman KM, Lessard CJ, Moser KL, 
Kimberly RP, Harley JB, Iannuzzi MC, Rybicki BA, Mont-
gomery CG. Genome-wide association study of African and 
European Americans implicates multiple shared and ethnic 
specific loci in sarcoidosis susceptibility.  PLoS One  2012; 
7:e43907-[PMID: 22952805].
7. Hosoda Y, Yamaguchi M, Hiraga Y. Global epidemiology of 
sarcoidosis. What story do prevalence and incidence tell us? 
Clin Chest Med  1997; 18:681-94. [PMID: 9413652].
8. Brewerton DA, Cockburn C, James DC, James DG, Neville 
E. HLA antigens in sarcoidosis.  Clin Exp Immunol  1977; 
27:227-9. [PMID: 849654].
9. Rossman MD, Thompson B, Frederick M, Maliarik M, 
Iannuzzi MC, Rybicki BA, Pandey JP, Newman LS, Magira 
E, Beznik-Cizman B, Monos D. HLA-DRB1*1101: a signifi-
cant risk factor for sarcoidosis in blacks and whites.  Am J 
Hum Genet  2003; 73:720-35. [PMID: 14508706].
10. Iannuzzi MC, Maliarik MJ, Poisson LM, Rybicki BA. 
Sarcoidosis susceptibility and resistance HLA-DQB1 alleles 
in African Americans.  Am J Respir Crit Care Med  2003; 
167:1225-31. [PMID: 12615619].
11. Zhu K, Yin X, Tang X, Zhang F, Yang S, Zhang X. Meta-
analysis of NOD2/CARD15 polymorphisms with psoriasis 
and psoriatic arthritis.  Rheumatol Int  2012; 32:1893-900. 
[PMID: 21448648].
12. Hofmann S, Franke A, Fischer A, Jacobs G, Nothnagel M, 
Gaede KI, Schurmann M, Muller-Quernheim J, Krawczak 
M, Rosenstiel P, Schreiber S. Genome-wide association 
study identifies ANXA11 as a new susceptibility locus for 
sarcoidosis.  Nat Genet  2008; 40:1103-6. [PMID: 19165924].
13. Hofmann S, Fischer A, Nothnagel M, Jacobs G, Schmid B, 
Wittig M, Franke A, Gaede KI, Schurmann M, Petrek M, 
Mrazek F, Pabst S, Grohe C, Grunewald J, Ronninger M, 
Eklund A, Rosenstiel P, Hohne K, Zissel G, Muller-Quern-
heim J, Schreiber S. Genome-wide association analysis 
reveals 12q13.3-q14.1 as new risk locus for sarcoidosis.  Eur 
Respir J  2013; 41:888-900. [PMID: 22936702].
14. Fischer A, Schmid B, Ellinghaus D, Nothnagel M, Gaede KI, 
Schurmann M, Lipinski S, Rosenstiel P, Zissel G, Hohne 
K, Petrek M, Kolek V, Pabst S, Grohe C, Grunewald J, 
Ronninger M, Eklund A, Padyukov L, Gieger C, Wichmann 
HE, Nebel A, Franke A, Muller-Quernheim J, Hofmann S, 
Schreiber S. A novel sarcoidosis risk locus for Europeans 
on chromosome 11q13.1.  Am J Respir Crit Care Med  2012; 
186:877-85. [PMID: 22837380].
15. Fischer A, Ellinghaus D, Nutsua M, Hofmann S, Montgomery 
CG, Iannuzzi MC, Rybicki BA, Petrek M, Mrazek F, Pabst S, 
Grohe C, Grunewald J, Ronninger M, Eklund A, Padyukov L, 
Mihailovic-Vucinic V, Jovanovic D, Sterclova M, Homolka J, 
Nothen MM, Herms S, Gieger C, Strauch K, Winkelmann J, 
Boehm BO, Brand S, Buning C, Schurmann M, Ellinghaus E, 
Baurecht H, Lieb W, Nebel A, Muller-Quernheim J, Franke 
A, Schreiber S. Identification of Immune-relevant Factors 
Conferring Sarcoidosis Genetic Risk.  Am J Respir Crit Care 
Med  2015; [PMID: 26051272].
Molecular Vision 2018; 24:59-74 <http://www.molvis.org/molvis/v24/59> © 2018 Molecular Vision 
73
16. Pabst S, Baumgarten G, Stremmel A, Lennarz M, Knufermann 
P, Gillissen A, Vetter H, Grohe C. Toll-like receptor (TLR) 
4 polymorphisms are associated with a chronic course of 
sarcoidosis.  Clin Exp Immunol  2006; 143:420-6. [PMID: 
16487240].
17. Birendra P. Sah and Michael C. Iannuzzi (2013). Genetic 
Factors Involved in Sarcoidosis S, Prof. Yoshinobu Eishi (Ed.), 
ISBN: 978-953-51-1027-9, InTech, DOI: 10.5772/55116. Avail-
able from: http://www.intechopen.com/books/sarcoidosis/
genetic-factors-involved-in-sarcoidosis.10.5772/55116
18. Thompson IA, Liu B, Sen HN, Jiao X, Katamay R, Li Z, Hu 
M, Hejtmancik F, Nussenblatt RB. Association of comple-
ment factor H tyrosine 402 histidine genotype with posterior 
involvement in sarcoid-related uveitis.  Am J Ophthalmol 
2013; 155:1068-74. .
19. Spagnolo P, Sato H, Marshall SE, Antoniou KM, Ahmad T, 
Wells AU, Ahad MA, Lightman S, du Bois RM, Welsh KI. 
Association between heat shock protein 70/Hom genetic poly-
morphisms and uveitis in patients with sarcoidosis.  Invest 
Ophthalmol Vis Sci  2007; 48:3019-25. [PMID: 17591867].
20. Kim HS, Choi D, Lim LL, Allada G, Smith JR, Austin CR, 
Doyle TM, Goodwin KA, Rosenbaum JT, Martin TM. Asso-
ciation of interleukin 23 receptor gene with sarcoidosis.  Dis 
Markers  2011; 31:17-24. [PMID: 21846945].
21. Asukata Y, Ota M, Meguro A, Katsuyama Y, Ishihara M, 
Namba K, Kitaichi N, Morimoto S, Kaburaki T, Ando Y, 
Takenaka S, Inoko H, Ohno S, Mizuki N. Lack of associa-
tion between toll-like receptor 4 gene polymorphisms and 
sarcoidosis-related uveitis in Japan.  Mol Vis  2009; 15:2673-
82. [PMID: 20011079].
22. Levin AM, Iannuzzi MC, Montgomery CG, Trudeau S, Datta 
I, McKeigue P, Fischer A, Nebel A, Rybicki BA. Association 
of ANXA11 genetic variation with sarcoidosis in African 
Americans and European Americans.  Genes Immun  2013; 
14:13-8. [PMID: 23151485].
23. Martin TM, Doyle TM, Smith JR, Dinulescu D, Rust K, Rosen-
baum JT. Uveitis in patients with sarcoidosis is not associ-
ated with mutations in NOD2 (CARD15).  Am J Ophthalmol 
2003; 136:933-5. [PMID: 14597055].
24. Herbort CP, Rao NA, Mochizuki M. members of Scientific 
Committee of First International Workshop on Ocular S. 
International criteria for the diagnosis of ocular sarcoid-
osis: results of the first International Workshop On Ocular 
Sarcoidosis (IWOS).  Ocul Immunol Inf lamm  2009; 
17:160-9. [PMID: 19585358].
25. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of 
Uveitis Nomenclature Working G. Standardization of uveitis 
nomenclature for reporting clinical data. Results of the First 
International Workshop.  Am J Ophthalmol  2005; 140:509-
16. [PMID: 16196117].
26. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, 
Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham 
PC. PLINK: a tool set for whole-genome association and 
population-based linkage analyses.  Am J Hum Genet  2007; 
81:559-75. [PMID: 17701901].
27. Hofmann S, Fischer A, Till A, Muller-Quernheim J, Hasler R, 
Franke A, Gade KI, Schaarschmidt H, Rosenstiel P, Nebel 
A, Schurmann M, Nothnagel M, Schreiber S. A genome-
wide association study reveals evidence of association with 
sarcoidosis at 6p12.1.  Eur Respir J  2011; 38:1127-35. [PMID: 
21540310].
28. Smith AC, Heo WD, Braun V, Jiang X, Macrae C, Casanova 
JE, Scidmore MA, Grinstein S, Meyer T, Brumell JH. A 
network of Rab GTPases controls phagosome maturation and 
is modulated by Salmonella enterica serovar Typhimurium. 
J Cell Biol  2007; 176:263-8. [PMID: 17261845].
29. Eishi Y, Suga M, Ishige I, Kobayashi D, Yamada T, Takemura 
T, Takizawa T, Koike M, Kudoh S, Costabel U, Guzman 
J, Rizzato G, Gambacorta M, du Bois R, Nicholson AG, 
Sharma OP, Ando M. Quantitative analysis of mycobacterial 
and propionibacterial DNA in lymph nodes of Japanese and 
European patients with sarcoidosis.  J Clin Microbiol  2002; 
40:198-204. [PMID: 11773116].
30. Song Z, Marzilli L, Greenlee BM, Chen ES, Silver RF, Askin 
FB, Teirstein AS, Zhang Y, Cotter RJ, Moller DR. Mycobac-
terial catalase-peroxidase is a tissue antigen and target of the 
adaptive immune response in systemic sarcoidosis.  J Exp 
Med  2005; 201:755-67. [PMID: 15753209].
31. Fatimathas L, Moss SE. Annexins as disease modifiers.  Histol 
Histopathol  2010; 25:527-32. [PMID: 20183805].
32. Buschow SI, van Balkom BW, Aalberts M, Heck AJ, Wauben 
M, Stoorvogel W. MHC class II-associated proteins in B-cell 
exosomes and potential functional implications for exosome 
biogenesis.  Immunol Cell Biol  2010; 88:851-6. [PMID: 
20458337].
33. Bianco NR, Kim SH, Morelli AE, Robbins PD. Modulation of 
the immune response using dendritic cell-derived exosomes. 
Methods Mol Biol  2007; 380:443-55. [PMID: 17876111].
34. Qazi KR, Torregrosa Paredes P, Dahlberg B, Grunewald J, 
Eklund A, Gabrielsson S. Proinflammatory exosomes in 
bronchoalveolar lavage fluid of patients with sarcoidosis. 
Thorax  2010; 65:1016-24. [PMID: 20880880].
35. Todd JA, Acha-Orbea H, Bell JI, Chao N, Fronek Z, Jacob CO, 
McDermott M, Sinha AA, Timmerman L, Steinman L. A 
molecular basis for MHC class II--associated autoimmunity. 
Science  1988; 240:1003-9. [PMID: 3368786].
36. Zeggini E, Packham J, Donn R, Wordsworth P, Hall A, 
Thomson W. Association of HLA-DRB1*13 with suscepti-
bility to uveitis in juvenile idiopathic arthritis in two inde-
pendent data sets.  Rheumatology (Oxford)  2006; 45:972-4. 
[PMID: 16495319].
37. Marquez A, Cordero-Coma M, Martin-Villa JM, Gorrono-
Echebarria MB, Blanco R, Diaz Valle D, Del Rio MJ, 
Blanco A, Olea JL, Cordero Y, Capella MJ, Diaz-Llopis 
M, Ortego-Centeno N, Ruiz-Arruza I, Llorenc V, Adan A, 
Fonollosa A, Ten Berge J, Atan D, Dick AD, De Boer JH, 
Kuiper J, Rothova A, Martin J. New insights into the genetic 
component of non-infectious uveitis through an Immunochip 
strategy.  J Med Genet  2017; 54:38-46. [PMID: 27609017].
Molecular Vision 2018; 24:59-74 <http://www.molvis.org/molvis/v24/59> © 2018 Molecular Vision 
74
38. El-Tahan RR, Ghoneim AM, El-Mashad N. TNF-alpha gene 
polymorphisms and expression.  Springerplus  2016; 5:1508-
[PMID: 27652081].
39. Lu S, Yan Y, Li Z, Chen L, Yang J, Zhang Y, Wang S, Liu 
L. Determination of Genes Related to Uveitis by Utilization 
of the Random Walk with Restart Algorithm on a Protein-
Protein Interaction Network.  Int J Mol Sci  2017; 18:[PMID: 
28505077].
Articles are provided courtesy of Emory University and the Zhongshan Ophthalmic Center, Sun Yat-sen University, P.R. China. 
The print version of this article was created on 21 January 2018. This reflects all typographical corrections and errata to the 
article through that date. Details of any changes may be found in the online version of the article.
